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ABSTRACT 
Symptoms onset in Amyotrophic Lateral Sclerosis (ALS) occur 
when over 70% of motor neurons is already lost, suggesting a relatively 
long pre-symptomatic phase. The description of several genes linked to 
ALS (e.g., SOD1, FUS, TARDP, C9orf72) has now allowed 
identification of pre-symptomatic carriers.  
These pre-symptomatic (or even preclinical) carriers can be 
followed up with the aim to identify the very early clinical disease-
related changes or a valuable biomarker. These efforts seem at present 
the best approach for the implementation of an early symptomatic 
therapy or for the disease prevention. 
 In this work, we studied the expression of FUS protein in cultured 
skin fibroblasts from pre-symptomatic FUS P525L mutation carriers. 
We cultured skin fibroblasts from two sisters belonging to an ALS 
family with FUS P525L mutation and carrying the same mutation, one 
healthy control and two patients with sporadic ALS (sALS), with no 
identified gene mutations. The two carriers were clinically 
asymptomatic, while the two patients fulfilled the El-Escorial and Awaji 
criteria for definite ALS. 
 Western blot and immunocytochemistry were performed with 
specific antibodies to study the expression and subcellular localization of 
FUS protein in the skin fibroblasts.  
In sporadic ALS, FUS protein showed an almost exclusive nuclear 
localization. In the healthy control, FUS was also mostly nuclear, with 
some cells showing a faint cytoplasmic expression. In the FUS P525L 
mutation carriers, the protein was strongly expressed in both nucleus and 
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cytoplasm in most cells, with a relatively high proportion of cells 
showing an exclusive cytoplasmic FUS localization. 
Furthermore, either heat-shock or dithiothreitol were applied to 
assess the effect of stress on FUS expression and cytoplasmic 
redistribution.  Stress induced cytoplasmic granules formation in all 
subjects, and FUS was recruited into them. After a single stress 
exposure, we observed in all subjects a time-dependent decrease of cells 
containing granules. However, granules persisted longer in fibroblasts 
from the two FUS P525L carriers, where the number of granules per cell 
was found to be higher than HC and sALS, suggesting that these 
granules may accumulate during chronic stress and thus be the 
precursors of the pathological FUS inclusions.  
These data might represent an early molecular change occurring 
before ALS onset, suggesting a transient pre-aggregative state. 
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1. Amyotrophic Lateral Sclerosis  
Amyotrophic lateral sclerosis (ALS) is the third most common 
neurodegenerative disease in the world. It is characterized by progressive 
neuronal loss and degeneration of upper motor neuron (UMN) and lower 
motor neuron (LMN) (figure 1). Patients affected with ALS typically 
suffer from progressive muscle weakness and atrophy and usually die 
from respiratory insufficiency within 2-3 years of symptoms onset. 
(Hong-Fu Li and Zhi-Ying Wu, 2016). ALS is an incurable disease and 
the only modifying therapy is limited to riluzole, with a modest effect on 
disease progression (Senda Ajround-Driss and Teepu Siddique, 2014). 
 
  
 
 
 
 
 
 
 
 
Fig. 1 Representation of upper and lower motor neuron. (Rowland 2011) 
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The incidence of the disease is 2-3 per year per 100.000 
population, with a risk of developing ALS of 1:350 for men and 1:400 
for women (S. Morgan and R.W. Orrell, 2016). 
The etiology of ALS is not fully understood, but many factors 
have been considered, including gene’s mutations, mitochondrial 
damage, oxidative stress, glutamate excitotoxicity, viral infection, 
protein aggregation, environmental factors (figure 2). In addition 
microglia and astrocytes seem to be involved (J JM LOan et al., 2012). 
 
 
 
 
 
Fig. 2  Cellular and molecular processes mediating neurodegeneration in ALS. 
The recent advances in research on ALS have established that the 
disease has a robust genetic basis (Kinsley L and  Siddique T., 2001; 
Renton AE1 et al., 2014) while the putative contribution of non-genetic 
risk factors is still under investigation (Ingre C et al., 2015; Al-Chalabi A 
et al., 2013; Bradley WG et al., 2013). 
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Since the identification of first causative gene in 1993, a growing 
number of ALS-causative genes associated with Mendelian inheritance 
have been identified. To date, at least 21 chromosomal regions 
containing 19 identified genes have been linked to ALS. These genes 
offered a unique opportunity to decipher the molecular mechanisms of 
neuronal degeneration (Senda Ajround-Driss and Teepu Siddique, 2014). 
In 90% of cases ALS is sporadic (sALS) and it is only in 10% of 
the case genetically transmitted (fALS) (figure 3). Among those 20% of 
fALS cases which are caused by the mutation in SOD1 gene, 4-5% of 
fALS cases are the result of mutations in TARDBP and FUS genes, more 
than 30% of fALS cases are associated with C9ORF72 mutations and the 
rest are due to the mutations in alsin, senataxsin, spatacsin, vesicle 
associated membrane protein associated protein B (VAPB), angiogenin 
(ANG), factor induced gene 4 (FIG4), optineurin (OPTN) and perhaps 
other unknown genes (table 1) (Chen S. et al., 2013). 
 
 
 
 
 
 
 
 
 
Fig. 3 – ALS genetic: 90%  of cases are sporadic (SALS);  10% are  FALS, with 
C9ORF72, SOD1, TARDBP and FUS being the main altered genes. 
C9orf72 
SOD1 
Unknown 
FUS 
TARDBP 
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Table 1. The genetic of fALS 
Among the genes involved in ALS, cu,znSOD1, FUS, TARDP 
and C9orf72 are those most frequently screened for mutations in familial 
and sporadic cases (Renton AE1 et al., 2014; Lattante S. et al., 2015). 
Furthermore, recent evidence suggests that the intermediate CAG 
expansions of the spinocerebellar ataxia-related genes, ATXN-1 and 
ATXN-2, are playing a role as genetic risk factors in the disease (Wang 
M-D. et al., 2014; Conforti FL et al., 2012). 
Similarly to other common neurodegenerative disorders, when 
ALS-related symptoms and signs start, the majority of the disease-
specific neurons (i.e., over 70%) are already lost (Arasaki K  and Tamaki 
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M., 1998; Brooks BR et al., 2000). Given that the onset of ALS is 
generally subtle, and because of the lack of a reliable biological marker, 
the diagnosis is often reached after a relatively long delay (Cellura E. et 
al., 2012) when further motor neurons are degenerated and the disease is 
generally in a full-blown stage.  
This has been one of the main reasons why nearly all clinical trials 
on ALS, carried out in the last twenty years, have repeatedly failed 
(Mitsumoto H. et al., 2014). 
 
 
 
It becomes therefore very important to understand the 
pathophysiological and the clinical changes occurring in ALS at the very 
beginning or even at the pre-symptomatic stage, in order to implement 
early and potentially effective therapeutic interventions (Benatar M. and  
Wuu J., 2012). 
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2. Fused in Sarcoma (Fus)  
Fused in sarcoma/translocated in liposarcoma (FUS/TLS) is an 
RNA/DNA binding protein involved in the pathogenesis of the 
neurodegenerative disorder amyotrophic lateral sclerosis. The FUS/TLS 
gene, localized on chromosome 16, consists of 15 exons and 14 introns 
(Morohoshi et al., 1998) and span about 12 Kb. 
 Chromosomal translocation of FUS/TLS was first found in human 
myxoid liposarcomas and acute myeloid leukaemia and results in the 
production of an oncogenic fusion protein formed  by the N-terminus of 
FUS and the DNA-binding domain of an endogenous transcription factor 
such as CHOP and ERG (Ichikawa et al., 1994; Crozat et al., 1993; 
Rabbitts et al., 1993).  
FUS belongs to the FET-protein family along with EWS (Ewing 
sarcoma) and TAF15 (TATA binding protein-associated factor 15 
(Bertolotti et al.,1996; Law et al., 2006; Tan & Manley, 2009). This 
family of proteins is involved in all stages of RNA metabolism, and also 
interacts with DNA and proteins. 
FUS gene is ubiquitously expressed in human tissues and in 
cultured cell lines but is absent from cardiac endothelium and muscle 
cells and melanocytes (Aman et al., 1996; Andersson et al., 2008; 
Morohoshi et al., 1998). The subcellular localization of the FUS/TLS 
protein is cell-type dependent. FUS/TLS is mainly a nuclear protein, but 
it is also present in the cytoplasm of many cells, except hepatocytes, 
where FUS/TLS is only present in the cytoplasm (Andersson et al., 
2008). 
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526 a.a. 
The molecular weight of human FUS protein is 53,426 daltons 
although it migrates as a band at approximately 70 kDa in SDS-PAGE. 
(Gal et al., 2011).  
FUS is a 526 amino acid multidomain protein composed of a Ser, 
Gly, Gln and Tyr-rich region containing degenerate repeats of S-Y-S-
G/Q sequences at the N-terminal region, a glycine-rich domain, RNA-
recognition motif (RRM), a zinc finger domain (ZFD), arginine-glycine-
glycine rich domains (RGG1, RGG2) and C-terminal nuclear localization 
signal (NLS) (Dormann D et al., 2012).   
 
 
FUS binds RNA in vitro and in vivo (Crozat, et al., 1993; Zinszner 
et al., 1997) and is involved in several mRNA-processing steps, such as 
transcription regulation (Uranishi et al., 2001), RNA splicing (Meissner 
et al., 2003), and RNA transport including nucleo-cytoplasmic shuttling 
(Zinszner et al., 1997).  
FUS also binds single- and double-stranded DNA and plays a role 
in DNA repair through homologous DNA pairing and recombination 
(Baechtold et al., 1999), and acts as a transcriptional regulatory sensor of 
DNA damage signals to assure genomic integrity (Wang et al., 2008).  
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FUS deficient mice indeed show high levels of chromosomal 
instability and perinatal mortality (Hicks et al., 2000) and an increased 
sensitivity to ionizing radiation (Kuroda et al., 2000).  
To date over 50 different FUS mutations have been identified in 
patients with ALS, and these mutations account for about 4% of fALS 
and 1% sALS cases in the Caucasian population (Liu X. et al., 2015). 
Many ALS-associated FUS mutations are mostly clustered in the 
C-terminal proline-tyrosine nuclear localization signal (PY-NLS) and 
impair Transportin-mediated nuclear import of FUS (Bentmann E. et al., 
2012). Generally, transportins bind to the nuclear localization signal 
(NLS) of FUS proteins in the cytoplasm. The transportin/FUS complexes 
cross the nuclear pore complex (NPC) through the interactions of the 
transportin with nucleoporins. In the nucleus, transportins are bound by 
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Ran-GTP, which releases FUS. Transportins are then recycled to the 
cytoplasm in association with Ran-GTP. On the cytoplasm face of the 
NPC, Ran hidrolyzes its bound GTP into GDP and dissociates, freeing 
the transportin for a new import cycle (Twyffels et al., 2014). 
 
 
 
 
 
 
 
 
 
 
Interestingly, mutations that show a very severe nuclear import 
defect, such as P525L, cause an unusually early disease onset and rapid 
disease progression, suggesting that impaired nuclear import of FUS is 
causally linked to the disease.  
So far, it is unclear whether reduced motor neuron (MN) survival 
in ALS patients is due to loss of nuclear function or gain of a still 
unidentified toxic function in the cytoplasm, or a combination of both 
(Lenzi et al, 2015). 
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3. Fused in Sarcoma (Fus) and Stress Granules  
Cytoplasmic inclusions containing Fused in Sarcoma (FUS) are a 
hallmark of ALS. The origin and nature of pathological inclusions 
remains poorly understood. It has been proposed that the formation of 
these pathological inclusions may be due to misregulation of the stress 
granules (SG) response. 
Stress granules are cytosolic structures that form transiently upon 
exposure of cells to stressful conditions, such as heat shock (42-44°C), 
osmotic shock, UV irradiation, or substances that elicit mitochondrial 
and/or oxidative stress (e.g. DTT) (Bentmann E. et al, 2012). SGs 
function to sequester, silence and/or degrade RNA transcript as part of a 
mechanism that adapts patterns of local RNA translation to facilitate the 
stress response (Wolozin et al., 2012). They contain polyadenylated 
RNA, small ribosomal sub-units, translation initiation factors (eIF3, 
eIF4E, eIF4G), and RNA binding proteins (RBPs) (Aulas A. et al., 
2015). Among the latter group, TIA-1 (T-cell restricted intracellular 
antigen-1) and G3BP1 (Ras GAP SH3 domain-binding protein 1) are the 
two most commonly studied and utilized SG markers (Kedersha et al., 
1999; Tourriere et al., 2003; Gilks et al., 2004). Finally, SGs dissolved 1-
3 hrs after the stress is removed, and were inhibited by cycloheximide 
treatment (Kerdersha et al., 1999).  
Many RNA binding proteins (FUS, TDP43, SMN) linked to 
neurodegenerative diseases associate with SGs in cell culture, and co-
localize with SG markers in cells undergoing stress. Mutations in RNA 
binding proteins appear to increase their propensity to aggregate and to 
form SGs (Wolozin 2012). 
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Recently, a two-hit model has been proposed to account for 
cytoplasmic FUS toxicity in ALS (Dormann et al., 2010). Cytoplasmic 
mislocalization of FUS, either through genetic mutations or other 
unidentified factors, represents the first hit. The first hit alone may not be 
sufficient to cause disease.  
However, a second hit (oxidation, heat- shock, viral infection or 
hypoxia) stemming from cellular stress directs cytoplasmic FUS into 
stress granules. 
 
 
  
 
A two hit model of FUS pathology. 
 
 
 
Localization of FUS to SGs is independent of its glycine-rich 
prion like domain but does require its capacity to bind mRNA (Anderson 
et al., 2008; Bentmann et al., 2012; Daigle et al., 2013). Intriguingly, 
mutant FUS localized to SGs will further recruit wild type FUS protein 
(Vance et al., 2013).  
So, cytoplasmic mislocalization of FUS protein, followed by 
cellular stress, contributes to the formation of cytoplasmic aggregates 
that sequester FUS, disrupt RNA processing and initiate motor neuron 
degeneration (Vance et al., 2013). 
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The aim of this study was to point out the presence of biochemical 
alterations among the members of a Sicilian family with FUS P525L 
mutation carriers, which might cause an aggressive form and an early 
onset of the disease.  
More specifically, we carried out a biochemical and 
immunocytochemical characterization of the FUS protein expression 
using primary cultures fibroblasts obtained through skin biopsy from 
FUS P525L mutation asymptomatic carriers in order to investigate 
possible alteration of the normal protein intracellular localization without 
signs or symptoms of the disease. We demonstrate that mutant P525L 
FUS is mislocalized to the cytoplasm of fibroblasts of the asymptomatic 
mutation carriers. Both wild-type and mutant FUS are sequestered into 
cytoplasmic foci after a stressful insult; however, the cytoplasmic 
granules of FUS P525L fibroblasts persist longer and appear more 
numerous, than those of healthy controls and sALS, suggesting a pre-
aggregative state. 
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SUBJECTS, MATERIALS AND METHODS 
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1. Subjects 
All subjects and patients involved in this study underwent a 
genetic counselling and gave their informed consent for the genetic 
testing and skin biopsy. All experiments were carried out according to 
the World Medical Association Declaration of Helsinki. 
A Sicilian ALS family carrying a FUS P525L was recently 
described in a collaborative study (Chiò et al., 2009). This FUS mutation 
is located at the C-terminus of the FUS protein, in the Nuclear 
Localization Signal (NLS) domain.  
As shown in Fig 1, in this family there were several members 
affected, and we could follow up the proband (IV-I), a girl with a bulbar-
onset form of the disease who died at the age of 22 years because 
respiratory failure. 
 Three healthy siblings of the proband (two sisters (IV-2 and IV-
5), turquoise circles in Fig. 1,  and one brother (IV-3), green square in 
Fig. 1, after a careful genetic counselling, took the decision to undergo a 
genetic testing for FUS P525L mutation. Sequencing of the FUS exon 
fifteen gene revealed that the two sisters, but not the brother, were 
carrying the P525L mutation.  The two sisters agreed to be submitted to 
a thorough clinical, biochemical and neurophysiological (i.e., EMG/ENG 
in the four limbs, including sternocleidomastoid and trapezius muscles, 
following the Awaji criteria (De Carvaho et al., 2008), and motor evoked 
potentials) workup in order to unveil signs and/or symptoms of ALS.  
The neurological examination did not disclose abnormalities; the 
biochemical and neurophysiological evaluations were all within normal 
range. A neurological, biochemical and neurophysiological follow-up 
was then planned to be performed every six months. At the time of this 
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study, we are at the third follow-up: the two IV-2 (mutation carrier 1, 
MC1) and IV-5 (mutation carrier 2, MC2) sisters are healthy, without 
signs or symptoms of motor neuron degeneration.  
The brother without mutation (IV-3) accepted to be a healthy 
control (HC) in this study (HC1). Another HC is a 58-year-old man 
(HC2), unrelated to the FUS P525L ALS family. 
We finally included two sporadic clinically-definite ALS patients, 
who had been diagnosed according to the current clinical and 
neurophysiological diagnostic criteria (De Carvaho et al., 2008; Brooks 
et al., 2000). 
 
 
  
 
 
 
 
 
 
Fig. 1  Pedigree of the family with P525L mutation 
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2. Skin biopsy and Human Fibroblasts Culture 
A punch biopsy was obtained from the volar region of the left arm 
of each subject enrolled. After having disinfected and anesthetized the 
interested area, the skin will be cut with the help of a biopsy punch, with 
a rotary and compressive movement. The obtained sample is put into a 
tube containing cold PBS, a phosphate buffer whose function is to slow 
down cellular metabolism and avoid oxidative stress. Each skin biopsy 
was then cut into four pieces, each of which was cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% calf serum, 
2 mM L-glutamine, 5 mM pyruvate, 100 U/mL penicillin and 100 µg/mL 
streptomycin. The medium was changed every three-four days until the 
fibroblasts were grown to confluence. Fibroblasts obtained from the skin 
biopsy were maintained in culture through passages on flask. The culture 
medium was changed every three days.  Each biopsy was coded to 
ensure subject’s anonymity. 
Fibroblast cultures, despite being peripheral cells, offer many 
advantages for the genetic and biochemical studies of neurological 
diseases as they are easy to cultivate, maintain and preserve. 
The cellular system of the in vitro cultured dermic fibroblasts allows us 
to: 
 study patients with similar cellular and molecular characteristics, 
which will be compared with those of cells obtained from non-
affected subjects (healthy control); 
 analyze the in vivo mutated proteins: an in vitro cellular system is 
a good model to study the in vivo organism, as some of the 
characteristics of the skin cells are maintained by the cultivated 
cells; 
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 study the effects of a genetic mutation causing the disease on the 
biological mechanisms activated in the cell, like for instance 
cellular survival, growth and migration. 
 
3. Stress induction 
Human fibroblasts were placed either on glass coverslips (for 
immunocytochemistry, cells and stress granules counting) and incubated 
twenty-four hours at 37°C in a 5% CO2 atmosphere. Two stress 
paradigms were used to acutely induce stress granule (SG) formation: i) 
a heat-shock, made by floating the cell plate in a 44°C pan of water in a 
CO2 incubator for one hour (Kedersha et al., 1999; Dorman et al., 2010); 
ii) a Dithiothreitol (DTT) treatment according to Maharjan et al. (2016). 
Shortly, cells were incubated with medium containing 3 mM DTT in a 
CO2 incubator for three hours to induce stress. DTT was then washed off 
by changing medium. Control cells were kept in the incubator. 
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4. Subcellular Fractionation 
Subcellular fractions (nuclei and cytoplasm) were prepared from 
human fibroblasts at ~ 80% confluence, as previously described  (La 
Bella et al., 2000) (figure 2). Cells were resuspended in RSB 100 Buffer  
(10mM Tris-HCl, pH 7.4; 100mM NaCl; 2.5mM MgCl2), containing 
protease inhibitors (Sigma, St. Louis, MO) and digitonin (40 µg/ml) and 
incubated for 10 minutes at 4°C. 
The digitonin stock solution was dissolved in ethanol because the 
alcoholic solution of digitonin forms insoluble complexes with 
cholesterol (plasma membrane) but it does not form these with 
cholesterol esters and then it preserves the nuclei. 
Cells were then disrupted by passage through a 25 G needle, and 
centrifuged at 900xg for 10 min at 4°C. The pellet obtained 
corresponded to the nuclei and the supernatant corresponded to the 
cytoplasm, see schema in Fig 2. Later the nuclei were resuspended in 
RSB 100 buffer with protease inhibitors . All fractions were finally 
equalized by volume and stored at -80°C until further use. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2  Flow chart for the subcellular fractionation. 
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5. SDS-page and Western blotting  
Subcellular fractions were thaw on ice, mixed with SDS-PAGE 
sample buffer, and boiled at 95°C for 5 min.  All samples were spun 
down for 2 min, loaded on to a 12% polyacrylamide gel and run at 35mA 
for about 1 h. Proteins were then electroblotted on to PVDF filters 
(0,45µm pore size, Millipore). Blots were blocked with 10% milk in PBS 
with 0,2% Tween-20 (PBS-T) for 2-3 h  at  room temperature, and then 
incubated with 1:1200 dilution polyclonal FUS antibody  (Proteintech 
Group, Inc., Chicago, USA) overnight at 4 °C. This antibody was raised 
against a peptide between amino acids 52 and 400 (GeneBank accession 
number: BC026062;). Secondary (HRP)-conjugated donkey antirabbit 
antibody (Chemicon, Damstadt, Germany) was used at a dilution of 1 : 
7000 in 1% milk/PBS-T.  
After washing the filters with PBS-T, protein bands were 
visualized using SuperSignal® West Pico Chemioluminescent Substrate 
(Pierce Biotecnology, Rockford, IL, USA). The detection of 
chemiluminescence was performed by ChemiDoc-It Imaging Systems 
(UVP, Cambridge, UK).  
In some experiments, filters were washed and stripped out of the 
bound antibodies (La Bella et al., 2000). After re-blocking, a membrane 
was reused for detection of α-tubulin,  a protein stained with a specific 
monoclonal antibody, at 1:1250 dilution (Sigma, St. Louis, MO), and the 
other for detection of SP1 ( 1:1000; Santa Cruz Biotechnology), a 
nuclear fraction marker. Densitometry of the immunoblots was 
performed with the Image J software. 
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6. Immunofluorescence 
Skin fibroblasts were cultured on glass coverslips until ~70% 
confluence. Fibroblasts from each subject were plated in duplicate. 
Cells were rinsed twice with ice-cold PBS and then fixed with 4% 
paraformaldehyde. After washing with PBS, cells were permeabilized 
with 0,5% Triton X-100 containing 50mM L-lysine in PBS and 
incubated with blocking buffer (4% BSA/2% horse serum in PBS). For 
immunofluorescence staining, cells were incubated overnight  with 
polyclonal FUS antibody (1:500; Proteintech Group, Inc., Chicago, 
USA).  
For double staining experiments and stress granules detection after 
stress induction, we used both a polyclonal FUS antibody and a 
monoclonal anti-TIA-R antibody (BD Transduction LaboratoriesTM, 
San José, CA, USA), a specific marker of stress granules, at 1:500 
dilution (Kawakami et al., 1992).  Cells were incubated with the primary 
antibodies overnight at 4°C. 
Cells were then washed with PBS containing 0.1% Triton X-100 
and then incubated with Cy3- conjugated donkey anti-rabbit antibody 
(1:1000;Chemicon Intl. Inc., Temecula, CA, USA) for 90 minutes at 
room temperature. The secondary antibody used for TIA-R detection was 
a FITC-conjugated donkey anti-mouse antibody at 1:500 dilution 
(Chemicon Intl. Inc., Temecula, CA, USA). 
After four rinses with PBS, coverslips were finally mounted on 
glass slides and stored at 4°C until analysis. 
Laser confocal microscopy was performed with a Zeiss LSM 5 
EXCITER confocal microscope with argon ion laser set at 548 nm for 
28 
 
Cy3 excitation or 495 nm for FITC excitation. Digitized series of optical 
sections were recorded and images for each staining reconstructed.  
 
7. Cell counting and subcellular FUS expression. 
For cell counting, coverslips with the coded fibroblasts from the 
two sporadic ALS (sALS), the two asymptomatic P525L mutation 
carriers and the healthy controls were placed under an Olympus 
Microscope with the fluorescence lamp set at 548 nm for Cy3 excitation 
and 495 nm for FITC excitation. 
The pattern of FUS staining  in the plated cells was categorized as 
follows: i) cells with exclusive nuclear FUS staining (the cytoplasmic 
staining being faint or absent); ii) cells with both a nuclear and a 
cytoplasmic staining; iii) cells with only a cytoplasmic staining.   
For each experiment, ~ 3000 cells from each subject were plated 
in duplicate. Two of us (MLB and FDF) blindly and independently 
recorded each pattern of staining present in 10 adjacent microscopic 
frames, i.e. 5 upward and 5 downward from the center of the rounded 
coverslip. A microscopic frame is an area delimited by a rectangle 
projected on the dish, and it is a tool of the inverted IX70 Olympus 
Microscope. Therefore, a relatively large microscopic field in each 
coverslip was analyzed twice. The agreement between the two counting 
researchers on the total number of cells per well was above 85%. 
Agreement for each pattern of staining was always above 90%.  
Each experiment was carried out in duplicate. 
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8. Evaluation of  the number cells containing stress granules 
    After stress induction with either heat-shock or DTT, the 
presence and morphology of the stress granules in immunofluorescence, 
using both FUS and TIA-R antibodies, was observed and recorded. Each 
glass coverslip was coded and the proportion of TIA-R-positive cells 
containing stress granules, over the total number of cells present in five 
consecutive microscopic frames, was independently counted by two of 
us (LBM and AN). The analysis was made at different times after the end 
of the stressful insult (i.e., T0, T1.5, T3.0, T4.5, T6.0, T9.0, T12 and T24 
hours). We took pictures of the five consecutive microscopic frames with 
an Olympus C-5060 Camedia digital camera. Pictures were then 
transferred to a computer for analysis. Inter-rater agreement was above 
88%; hence, data from the two independent counts were pooled together. 
 
9. Evaluation of the number of stress granules per cell 
    The number of granules per cell was also counted. Shortly, each 
coverslip was coded, and after a single stress insult, cells were double 
stained for FUS and TIA-R at different time points (i.e., T0, T1.5, T3.0, 
T4.5, T6.0 hours). Pictures of 20 individual FUS- and TIA-R-stained 
cells, present in two-three adjacent microscopic frames of the IX70 
Olympus microscope, were taken.  
    Pictures were transferred to a computer and two of us (MLB 
and AN), blind for the experiment, independently counted the number of 
TIA-R-positive granules per cell at each time point after stress.   
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10. Data analysis and statistics 
    Data obtained by counting the cells showing the different 
patterns of FUS staining in each subject were calculated as the percent of 
the total number of counted cells and expressed as mean + SD of three 
separate experiments. Data from either the two HCs or the two sALS 
were pooled. Given the high level of agreement between the two 
counting researchers, the data from each duplicate count were pooled.  
    The proportion of cells containing granules at different times 
after stress insults, in each subject group, was represented as mean + SD 
of two different experiments. Data from each FUS P525L mutation 
carrier were analyzed individually. Finally, the number of granules per 
cell at different times after stress insults were expressed as mean + SD of 
20 cells per subject in two independent experiments. Data from the 
healthy subjects and sALS were pooled.  
    For the statistical analysis, we used the SIGMASTAT 3.5 
software package (Systat Software Inc., San Jose, CA, USA). 
Differences in the proportion of the different patterns of FUS staining, 
the granule-containing cells and the number of granules per cell for each 
subject group were analyzed with one-way ANOVA, followed by post-
hoc Dunnett’s analysis. p values <0.05 were considered significant.  
 
 
 
 
 
31 
 
 
 
 
 
 
 
 
 
RESULTS  
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The fibroblasts cultured from the skin biopsies of the healthy 
subject, the two FUS P525L mutation carriers and the two sporadic ALS 
showed a similar gross morphology. Cells were apparently healthy in 
culture.   
 
 
 
 
 
 
 
 
 
 
 
Fig.1 Fibroblasts from the IV-2 FUS P525L mutation carrier. 
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1. FUS is mislocalized to cytoplasm in cells of asymptomatic FUS 
P525L mutation carriers 
To study the subcellular localization of FUS protein in the skin 
fibroblasts, we used the digitonin method to isolate the nuclei from the 
whole cytoplasm (Fig.2). The two nuclear and cytoplasmic fractions 
were equalized by volume. 
 
 
 
 
 
 
 
 
Fig. 2 Nuclei  
 
We then performed immunoblot studies with a polyclonal anti-
FUS antibody and found a relatively strong FUS protein expression in 
the nuclear fraction of all samples examined (Fig 3A e 3B). FUS 
expression in the cytosol extracts was instead very different between 
samples.  
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Fig.3 Differential expression of FUS protein in the nuclei (N) and cytoplasm (C) of 
fibroblasts from the two FUS P525L mutation carriers (MC1 and MC2), a healthy 
control (HC) and two sALS patients. Fractions were incubated with a polyclonal 
anti-FUS antibody. α-Tubulin and Sp1 antibodies marked the cytoplasm and nuclear 
fractions, respectively.(C) Densitometric analysis of the relative FUS-related band 
intensity of the nuclear and cytoplasmic fractions from HC, MC1, MC2 and sALS. 
Data are expressed as mean + SD of three independent blots. * p < 0.05 one-way 
ANOVA with post-hoc Dunnett’s analysis. 
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Cytosolic FUS protein expression was strong in the two FUS 
P525L mutation carriers, faint in the healthy subject and almost absent in 
the two sporadic ALS. Therefore, FUS protein appears specifically  
mislocalized in the cytoplasm of preclinical FUS P525L mutation 
carriers. α-tubulin and Sp1 antibodies allowed identification of the 
nuclear and cytoplasmic fractions (Fig 3A).  
The relative densitometry of the FUS-related bands in the nuclear 
and cytoplasmic fractions confirmed that the protein level was 
significantly higher in the cytoplasm of the two FUS P525L mutation 
carriers compared to the HCs and sALS (p < 0.05 one-way ANOVA 
with post-hoc Dunnett’s analysis; Fig. 3C). 
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To further confirm the subcellular mislocalization of FUS protein 
in the two preclinical FUS P525L mutation carriers, we performed 
immunocytochemical studies on the cultured skin fibroblasts. 
 
 
 
Fig. 4 FUS mislocalization to the cytoplasm of the fibroblasts of FUS P525L 
mutation carriers. (A) Representative confocal images of immunoﬂuorescence 
experiments performed with the polyclonal anti-FUS antibody on ﬁbroblasts from the 
healthy control # 2, FUS P525L mutation carrier 1 and sporadic ALS 1. (B) 
Comparison of the number of cells expressing FUS in the nucleus (N) only, in the 
cytoplasm (C) only or in both nucleus and cytoplasm (N + C). hatched bars: healthy 
control (pedigree # IV-3; black bars: FUS P525L carrier 1 (pedigree # IV-2); white 
bars: FUS P525L carrier 2 (pedigree # IV-5); grey bars: sporadic ALS (combined # 
1 and # 2). Data are expressed as % of the total analyzed cells (mean + SD of three 
separate experiments done in duplicate wells). * p < 0.05 one-way ANOVA with 
post-hoc Dunnett’s analysis. 
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Fig. 4A shows the pattern of FUS staining in representative cells 
of the different subjects studied. In the healthy subject (HC2), FUS was 
expressed in the nucleus in almost all cells. A weak cytoplasmic staining 
was seen in about twenty percent of the cultured cells.  
In the FUS P525L mutation carriers, most cells (i.e., over 70 
percent) showed a diffuse nuclear and cytoplasmic staining, with about 
ten percent of the cultured cells with an exclusive cytoplasmic staining. 
Cells with an exclusive nuclear staining were a minority in these 
subjects. Finally, in fibroblasts from sALS, FUS was mostly expressed 
in the nucleus, with a few cells showing a concomitant nuclear and a 
cytoplasmic staining. Nuclear or cytoplasmic aggregates were not seen 
in any of the cultured cells. 
In the majority of cells from the two preclinical FUS P525L 
mutation carriers, FUS was expressed in both nucleus and cytoplasm at a 
percent significantly higher than the healthy subject and the two sporadic 
ALS patients (p < 0.05 one-way ANOVA with post-hoc Holm-Sidak 
analysis) (figure 4B). 
These experiments further demonstrate that FUS is mislocalized in 
the cytoplasm of presymptomatic FUS P525L mutation carriers. 
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2. Cellular stress induces cytoplasmic FUS recruitment into stress 
granules 
The evidence that C-terminal FUS mutations can lead to protein 
recruitment into stress granules (Dormann et al., 2010; Vance et al., 
2013), prompted us to study the effect of stress on wild-type and the 
mutant P525L FUS proteins redistribution in the cells. Heat-shock and 
DTT were the two stressors used to transiently insult the fibroblasts. 
TIA-R antibody was used as a marker of the stress granules. In control 
conditions, FUS was mostly nuclear in sALS and HCs, while, as 
expected, the mutated protein was diffusely expressed in the cytoplasm 
of the MC1 and MC2 fibroblasts (Fig 5A, D, G, J and Fig 6A, D, G, J). 
TIA-R showed in all control cells a nuclear and cytoplasmic staining 
(Fig 5B, E, H, K and Fig 6B, E, H, K). Merging the pictures highlighted 
a co-localization of both proteins in the nucleus and, for the FUS P525L 
fibroblasts, in the cytoplasm (Fig 5C, F, I, L and Fig 6C, F, I, L). 
 
5 
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Fig. 5 e 6 Cytosolic FUS is recruited to SG upon treatment with various stressors. 
Fibroblasts were subjected to dithiothreitol (DTT) 3mM for 3 hrs (A) and to heat 
shock (44°C) for 1 h (B). Cells were fixed and stained with antibody anti-FUS (red) 
and anti-TIAR (green). Stress induced cytoplasmic granules formation in all 
subjects, and FUS was recruited into them. 
 
 
 
 
Heat-shock (44°C, one hour) induced the appearance of TIA-R-
positive stress granules, but with a heterogeneous morphology: a number 
of cells showed a diffuse cytoplasmic micro-granulation (e.g., Fig. 5B1, 
K1), while in other cells stress granules appeared well rounded (e.g., Fig. 
5E1, H1). Note that this heterogeneous pattern of stress granules was 
detectable in the fibroblasts of all subjects under study (i.e., healthy 
controls, sALS patients, asymptomatic FUS P525L mutation carriers), 
the proportion of cells showing the micro-granulation being slightly 
predominant (data not shown).  
In fibroblasts of sALS, stress induced FUS redistribution to the 
cytoplasm (Fig. 5A1), where it fully co-localized with TIA-R into stress 
granules (Fig. 5C1). In cells of the HCs, FUS remained mostly nuclear 
6 
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(Fig. 5D1) where it overlapped with TIA-R (Fig. 5F1). In the fibroblasts 
of MC1 and MC2, mutated P525L FUS co-localized with TIA-R into 
stress granules, both in the micro-granules or in bigger, punctuate, 
granules (Fig. 5G1, H1, I1 and Fig 5J1, K1, L1).  
We conclude that heat-shock induces in fibroblasts the appearance 
of either diffuse micro-granules or dotted stress granules, and that it 
causes FUS redistribution into the cytoplasm of the cells from sALS 
patients. When localized to the cytoplasm, FUS is fully recruited into 
stress granules, irrespective of their specific morphology.  
When 3mM DTT was used as stressor, all fibroblasts, irrespective 
of the subject they were derived from, showed TIA-R-positive dotted 
stress granules in the cytoplasm (Fig. 6B1, E1, H1, K1). FUS remained 
mostly nuclear in HCs, with a very few FUS-positive granules detectable 
(Fig. 6D1); in sALS, the protein relocated to the cytoplasm and in stress 
granules (Fig. 6A1). Merging the pictures revealed FUS-TIA-R co-
localization only in the nucleus for HCs (Fig. 6F1) and in the stress 
granules for sALS (Fig 6C1). Similarly, DTT stress induced a full 
recruitment of cytoplasmic mutated P525L FUS  into stress granules 
(Fig. 6G1 and J1) where it co-localized with TIA-R (Fig. 6H1, K1) in all 
cells: see merged FUS-TIA-R pictures in Fig.6 I1 and L1. Therefore, the 
two stress paradigms confirm that cytoplasmic FUS, either wild-type or 
with P525L mutation, can be recruited into stress granules. 
 
 
 
 
 
 
41 
 
3. Cell viability and proliferation after stress induction 
 
After the end of the stressful insult we counted cells at different 
time (i.e., T0, T1.5, T3.0, T4.5, T6.0, T9.0, T12 and T24 hours). We 
observed that fibroblasts from all subjects appeared to be able to 
eventually recover after 6 hours from the heat stress treatment, but they 
underwent a growth arrest following treatment with DTT (figure 7). So, 
with regards to cell viability and proliferation, fibroblasts from our 
subjects with FUS P525L mutation were not more susceptible to damage 
from heat shock and DTT than heathy control and sALS.  
 
 
Fig 7.  Effect of HS (44°C, 30 min ) and DTT exposure (3 mM/3 hrs) on cell viability 
and proliferation. 
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4. Long persistence of the stress granules in the cytoplasm of FUS 
P525L fibroblasts 
Recently, it has been suggested that FUS mutated at the C-
terminal may induce neurodegeneration through a two-hit mechanism, in 
which FUS can be permanently sequestered into stress granules (Buratti 
& Baralle, 2010; Dorman et al., 2010). This hypothesis prompted us to 
verify whether cytoplasmic FUS, either wild type or mutated, when 
recruited into stress granules after acute stress, would lead to a 
pathological persistence of these structures in the fibroblasts.  
As DTT-induced stress always led to a homogeneous appearance 
of discrete foci in the cells, to avoid any miscounting we chose this stress 
paradigm to evaluate the proportion of fibroblasts containing TIA-R-
positive granules at different times after the stressful insult. 
 
 
 
 
 
 
 
 
 
Fig. 8 Percent of cells with stress granules after DTT treatment. 
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As shown in Fig 8, immediately after stress (T0) almost all cells 
contained granules, irrespective of the subject the fibroblasts came from. 
However, while the granule-containing cells of the HCs rapidly 
decreased, becoming negligible 9 – 12 hours after stress, the proportion 
of granule-containing cells in the FUS P525L fibroblast population from 
the two mutation carriers (MC1 and MC2) remained significantly higher 
than the HCs up to 4.5-6 hours after the insult (p < 0.05 at 1.5, 3.0 and 
4.5 hours after stress for FUS P525L fibroblasts from carrier 1 and 
carrier 2 vs pooled healthy controls, one-way ANOVA with post-hoc 
Dunnett’s analysis).  
Note that at 6.0 hours after stress, the FUS P525L fibroblast 
population from MC1 showed a proportion of cells with granules 
significantly higher than all other groups.  
The fibroblasts from the two sALS patients (data were pooled) 
showed an intermediate behavior. Cells containing FUS-positive stress 
granules decreased over time, but at a rate slightly slower than the HCs 
(Fig. 8).  
A 9.0 hours after stress or later (cells were counted up to 24 hours) 
no differences between groups could be seen, the proportion of granule-
containing cells being very low in all. 
To further evaluate the time course of the DTT-induced stress 
granules in the fibroblasts, we counted for each subject the number of 
TIA-R-positive granules per cell. 
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As shown in TAB. I, immediately after the stress insult, the 
number of cytoplasmic stress granules per cell was not different among 
groups. However, while the number of granules regularly decreased in 
fibroblasts of HCs and sALS patients, it remained relatively high in the 
FUS P525L fibroblasts even at six hours after stress (p < 0.05 at 1.5, 3.0, 
4.5 and 6.0 hours after stress for FUS P525L fibroblasts from MC1 and p 
< 0.05 at 1.5 and 6.0 hours after stress for FUS P525L fibroblasts from 
MC2, both vs pooled healthy controls; one-way ANOVA with post-hoc 
Dunnett’s analysis). 
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 We conclude that stress granules tend to persist in the FUS P525L 
fibroblasts and, to lesser extent, in sALS fibroblasts. Therefore, when the 
mutated FUS P525L protein is recruited into stress granules, it might 
induce in the cells a transient pre-aggregative state.  
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DISCUSSION 
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This study presents, at our knowledge, the first evidence of a 
cytoplasmic mislocalization of FUS in skin fibroblasts of 
presymptomatic FUS P525L mutation carriers. Acute stress induced 
cytoplasmic FUS recruitment into stress granules. The granules 
containing the mutant P525L FUS persist in the cells longer than 
granules with wild-type FUS, suggesting a transient pre-aggregative 
state. This condition is likely to be a necessary step, though not 
sufficient, to induce motor neuron degeneration. These results support 
the two-hit hypothesis of mutant FUS-mediated motor neuron 
degeneration, in which FUS-containing stress granules may transform 
into permanent aggregates when either a long-lasting stress or another 
type of cellular insult is applied (Buratti & Baralle, 2010; Dorman et al., 
2010; Aulas & Vande Velde, 2015).  
FUS is a 526 aminoacid protein that was originally described as a 
component of a fusion oncoprotein associated with liposarcoma (Crozat 
et al., 1993), and it is involved in RNA transcription, processing and 
transport (Crozat et al., 1993; Renton et al., 2014). Furthermore, FUS is 
also involved in mRNA export and mRNA transport to neuronal 
dendrites (Fujii & Takumi, 2005). 
In human neurons, FUS is physiologically present in the nucleus, 
with a low level of  expression in the cytoplasm. A very similar profile 
has been also detected in the skin fibroblasts (Andersson et al., 2008). 
Recently, it has been shown that mutations in the FUS gene are 
responsible for some 5% of familial and 1% of sporadic ALS (Renton et 
al., 2014; Lattante et al., 2015). Mutant FUS protein has been observed 
in cytosolic inclusions in motor neurons, with a concomitant reduction of 
its nuclear staining (Kwiatkowski et al., 2009; Vance et al., 2009; 
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Bäumer et al., 2010). Furthermore, FUS appears to be misplaced to the 
cytoplasm of cells transfected with the mutant protein (i.e., R521C, 
R521H, R521C) (Kwiatkowski et al., 2009; Vance et al., 2009),  in 
neurons of ALS patients with P525L mutation (Bäumer et al., 2010; Ito 
et al., 2011) and skin fibroblasts from patients carrying the R521C 
mutation and mutations in the 3’ untranslated region of the gene 
(Sabatelli et al., 2013). In fibroblasts of subjects with sALS, FUS 
maintains an nearly exclusive nuclear expression (Sabatelli et al., 2013; 
Kariya et al., 2014). 
Our study shows that in the fibroblasts of sporadic ALS patients, 
with no known mutations, FUS is expressed in the nucleus, whereas in 
the healthy subject the protein shows also a weak, though detectable, 
cytoplasmic localization, a data fully consistent with other published 
works (Ito et al., 2011; Andersson et al., 2008; Kariya et al., 2014).  In 
the two presymptomatic FUS P525L mutation carriers, FUS protein 
appears heavily misplaced to the cytoplasm, a biochemical abnormality 
similar to that reported with patients with symptomatic ALS and 
carrying FUS mutations  (Kwiatkowski et al., 2009; Vance et al., 2009; 
Bäumer et al., 2010; Ito et al., 2011; Sabatelli et al., 2013). 
However, while P525L FUS cytoplasmic mislocalization 
represents a specific biochemical signature of the mutation in the 
asymptomatic carriers, it is not an indicator of an ongoing 
neurodegenerative process. Mislocalized P525L FUS in these cells is, in 
fact, the result of the altered NLS domain that prevents the protein 
translocation to the nucleus (Dorman et al., 2010). It basically denotes 
the presence of the mutation. 
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The molecular pathway involving mutated FUS and leading to the 
motor neuron degeneration is still imperfectly known. However, it has 
been suggested that a putative early event might be the abnormal 
assembling of the cytoplasmic misplaced protein into stress granules 
(Dorman et al., 2010; Vance et al., 2013; Aulas & Vande Velde, 2015; 
Lenzi et al., 2015). 
Stress granules are transient cytoplasmic foci containing RNA-
binding proteins, mRNA, non-translating messenger ribonucleoproteins 
and several translation initiation factors, that assemble in response to a 
variety of cellular stresses (Anderson & Kedersha, 2009). Granule 
disassembling occurs when the stress insult is terminated.  
We challenged the fibroblasts from the different subjects with two 
acute stress paradigms, i.e., heat-shock and DTT, and found that all cells 
reacted by forming TIA-R positive cytoplasmic stress granules. TIA-R is 
a specific marker of the stress granules (Kedersha et al., 1999; Anderson 
& Kedersha, 2009). Noteworthy, TIA-R/mutant P525L FUS-positive 
granules persisted in the cells longer, and they were more abundant than 
the cells from healthy controls and sALS patients with TIA-R/wild-type 
FUS-positive granules, suggesting a dose-effect. That is, the more FUS 
present in the cytoplasm the higher amount recruited into the stress 
granules. This explains why we observed more DTT-induced granules in 
the mutant FUS P525L fibroblasts than in the healthy controls. 
In addition, we found no evidence of toxicity associated with 
treatment with stressors, as measured by cell counting. In particular 
fibroblasts from all subjects appeared to be able to eventually recover 
after 6 hours from the heat stress treatment, but they underwent a growth 
arrest following treatment with DTT (Pani et al., 2000). 
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 Interestingly, in fibroblasts of sALS patients, acute stress (either 
heat-shock or DTT exposure) induced a cytoplasmic redistribution also 
of the wild-type FUS which then assembled into stress granules. 
However, this occurred to a lesser extent than asymptomatic FUS P525L 
mutation carriers. An indirect support to this result comes from the 
demonstration that wild-type FUS can be found in cytoplasmic 
inclusions, containing other proteins (i.e., TDP-43, ubiquitin, p62) and in 
skein-like inclusions in motor neurons of sporadic ALS (Deng et al., 
2010; Keller et al, 2012). Most data on the effect of stress on the FUS 
cellular expression have been obtained with transfections of the wild-
type FUS gene on cell lines or using cells from healthy controls (Dorman 
et al., 2010; Ito et al., 2011; Vance et al., 2013), showing a pattern of 
staining similar to what we have seen on cells from our healthy controls. 
This might not be true for the sALS cells, were other putative disease-
related variables may cooperate in facilitating FUS mislocalization to the 
cytoplasm and recruitment to stress granules under stress conditions.  
We suggest that the FUS-positive stress granules, either from the 
sALS or the mutation carriers, might actually represent an early step 
towards the development of the cellular inclusions observed in both 
sALS and mutant FUS motor neurons (Kwiatkowski et al., 2009; Vance 
et al., 2009; Bäumer et al., 2010; Deng et al., 2010; Keller et al, 2012).  
The stress granules in the fibroblasts of asymptomatic FUS P525L 
mutation carriers might, therefore, represent a pre-aggregative state of 
the FUS protein. This condition is reversible, and it is certainly not 
sufficient to explain the whole neurodegenerative process leading to 
motor neuron cell death in FUS P525L ALS. Also, fibroblasts may not 
be suitable for the study of all neurodegenerative changes leading to 
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motor neuron death. Yet, they remain at present the best model for the 
evaluation of some ALS-related mechanistic processes in living ALS 
patient and in an asymptomatic ALS gene mutation carriers. An alternate 
possibility could be the use motor neurons derived from stem cells from 
fibroblasts of either ALS patients or asymptomatic mutation carriers 
reprogrammed to a pluripotent state (Dimos et al., 2008; Favarelli et al., 
2014; Lenzi et al., 2015). This approach, although not a laboratory 
routine, is worth a focused effort in the near future, as it may help the 
disclosure of specific neurodegenerative pathways in asymptomatic 
mutation carriers.  
The two sisters with FUS P525L mutation are now in their third 
year of follow up, and they are still asymptomatic; the repeated 
diagnostic workups have been negative. As the FUS P525L mutation is 
known to be particularly aggressive (Conte et al., 2012), a careful 
surveillance is performed to detect very early clinical, 
neurophysiological and biochemical changes indicating the onset of the 
disease. Unfortunately, we could not obtain fibroblasts from the proband 
(IV-1 in the pedigree of the FUS P525L family,.), which could have 
given useful information about the biochemical changes in a subject with 
the actual disease.  
All biochemical changes we have seen up to now in the fibroblasts 
of the asymptomatic FUS P525L mutation carriers might represent early 
steps of the neurodegenerative process, being, however, insufficient to 
explain it fully. Moreover, they cannot at present be adopted as 
preclinical biomarkers of the disease. 
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FINAL CONCLUTIONS AND FUTURE PROSPECTS 
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During my PhD period at the Laboratory of Neurochemistry 
Laboratory, Department of Experimental Biomedicine and Clinical 
Neurosciences, University Hospital "Paolo Giaccone" in Palermo,  I 
worked on the study of the expression and characterization of FUS 
protein in fibroblasts of ALS patients and FUS P525L mutation carriers. 
I have come to the following conclusions: 
 Molecular abnormalities occur early in fibroblasts of preclinical 
asymptomatic FUS P525L mutation carriers (aggressive mutation 
in the FUS gene); 
 Mislocalization of FUS protein takes place in absence of signs 
and/or symptoms of motor neuron degeneration; 
 Cytoplasmic granules form in all subjects following acute stress, 
and FUS recruitment into them. 
 Granules persist longer in fibroblasts from the two FUS P525L 
carriers, and number of granules per cell is higher than HC and 
sALS. 
These represent important biochemical changes suggesting a role 
of the protein as a preclinical molecular signature before the disease 
onset.  
This may provide new biological and pathological insights into the 
understanding of the pathogenesis of FUS-related ALS and prevent, 
through targeted therapeutic strategies, motor neurons degeneration. 
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Future Prospects: 
 
As this study showed that mutated FUS protein is recruited into 
stress granules, suggesting a transient pre-aggregative state, we will 
more investigate in order to understand mechanisms involved in the 
switching in pathological FUS inclusions. 
To reach these aims we will proceed as follow: 
 To expose fibroblasts to repeated and chronic stresses; 
 To inhibit the formation of stress granules with cycloheximide or 
emetine; 
 To modulate, with activators or inhibitors, autophagic process: 
failure to clear stress granules by autophagic processes may 
promote ALS pathogenesis. 
 
Simultaneously we will study the eventual role of the cellular 
senescence in subcellular distribution of FUS protein. 
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